Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Trial Profile

Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs ANAVEX 2-73 (Primary) ; ANAVEX 2-73 (Primary) ; ANAVEX-2-73/donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Anavex Life Sciences
  • Most Recent Events

    • 19 Jan 2017 Status changed from active, no longer recruiting to completed, according to an Anavex Life Sciences media release.
    • 12 Dec 2016 According to an Anavex Life Sciences Corp media release, 9-Months and 12-Months Safety and Exploratory Efficacy Data was presented at the 9th annual Clinical Trials on Alzheimer's Disease (CTAD) 2016 conference.
    • 08 Dec 2016 Results at 57-week published in an Anavex Life Sciences Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top